Market Cap 452.48B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 24.87
Forward PE 17.87
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 1,935,161
Avg Vol 7,042,922
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 57%
Beta 0.30
Analysts Strong Sell
Price Target $264.62

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
VeltrixCapitalOfficial
VeltrixCapitalOfficial Jul. 23 at 3:29 PM
$ABBV $ABBV @.25 | +120% đŸ”„đŸ”„đŸ”„ SOLD MOST , LEFT RUNNERS
0 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial Jul. 23 at 2:47 PM
$ABBV @.18 | +60% đŸ”„đŸ”„đŸ”„ SOLD MOST , LEFT RUNNERS TURN MY NOTIFICAITONS ON
0 · Reply
liamsniperalert
liamsniperalert Jul. 23 at 2:16 PM
7/24 $ABBV 265c @​ .13
0 · Reply
stagetwotrading
stagetwotrading Jul. 23 at 1:22 PM
$ABBV - Grade A+ Stop loss @ 236.72
0 · Reply
10xorbust
10xorbust Jul. 23 at 10:53 AM
$SLS the entire purpose of bear posts like this is to scare new investors into selling. Those of us have been here for a long time tend to ignore these posts and are completely un persuaded. The purpose of this response is for the benefit of the new investors who are the targets of this nonsense. First of all with a username like Seedy do we really need to say more? Seedy is pretty much exactly what the content is of this user’s substance. Seedy’s “high probability of failure” thesis is a house of cards built on a foundations of quicksand - a sea of assumptions being presented as facts. They are no such thing. First, Seedy is assuming the BAT arm of Regal is dramatically outperforming because the trial has taken longer than expected. Nonsense. Regal is still blinded. Nobody outside the IMDC knows whether the longer survival is coming from GPS, BAT, or both. Saying “the control WILL outperform” isn’t analysi - it’s speculation. ïżŒ Moreover the historical studies of how BAT performs ïżŒ and maintaining remission or not on CD side, they cut the other way and demonstrate that these drugs do not maintain remission for long periods of time, especially at the CR2 stage. Indeed, when the leading BAT drugs in Regal, Ven/Aza were put through a phase 3 clinical trial for AML remission maintenance, the manufacturer HALTED the trial midstream - citing low enrollment. Surely, $ABBV a major pharmaceutical company with every financial incentive for this trial to finish if it were to be successful and put these drugs on the market for CR two maintenance could’ve and would’ve solved this problem if it thought the trial would be successful. Second, Seedy completely ignores the evidence that supports GPS while highlighting only the negatives. The Phase 2 AML CR2 study for GPS showed survival that was several times longer than historical controls and is the entire reason Regal exists. Does that guarantee success? Of course not. But pretending it never happened isn’t an honest review of the data. It is nothing but bear FUD. Seedy also treats every prior GPS study as a “failure,” which simply isn’t true. Several studies demonstrated strong WT1 immune responses and encouraging survival signals but were small, early-stage trials that weren’t designed to prove efficacy. There’s a huge difference between “not statistically definitive” and “the mechanism doesn’t work.” Seedy also ignores the growing body of evidence that WT1 vaccines can generate meaningful anti-leukemia immune responses. The recent pediatric WT1 vaccine study produced excellent long-term survival and showed that patients who mounted an immune response lived dramatically longer. Different study? Yes. Different vaccine? Yes. But it directly contradicts the claim that WT1 vaccines are biologically incapable of working. Seedy’s statistical argument is misleading too. He’s acting as if Regal was designed with “no cushion.” That’s not how clinical trials work. The 0.636 hazard ratio in Regal which defines success is simply the statistical hurdle needed to declare success—not a prediction of where GPS will actually land. Finally, if the bear case is so obvious, why has Regal’s independent Data Monitoring Committee repeatedly allowed the trial to continue? They have seen the unblinded data. They stopped neither for futility nor for safety concerns. That doesn’t mean Regal will succeed—but it certainly doesn’t support the claim that failure is virtually inevitable. In short, Seedy tortures the evidence and does gyrations to back into his conclusion that Regal will fail. His calling failure a “high probability” while ignoring the strongest supporting data, dismissing positive studies, and presenting speculation as fact isn’t objective analysis—it’s cherry-picking. There are no guarantees in any phase 3 clinical trial. Regal included. But at least to me, Seedy has presented nothing making me believe that Regal is going to fail. To me the evidence points strongly the other way. To me there is no super BAT and the incredibly long survival of approximately 40% of the Regal patients a minimum of 28 months to move four years cannot be explained by BAT. Finally, are Pharma Bro and “Seedy” the same person? I don’t know that, of course. But it certainly wouldn’t shock me. Once a convicted securities fraudster with a LIFETIME BAN from the pharmaceutical industry always a securities fraudster. Of course, this is not financial advice and do your own due diligence.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jul. 23 at 2:01 AM
$SLS $ABBV $GSK $VRTX $MRK AbbVie paid a 49% premium for a drug with zero approvals. Here's why that's completely rational. Recently, AbbVie announced it would acquire Apogee Therapeutics for $10.9 billion, its largest buyout in over five years, according to Reuters. AbbVie is not alone. In 2026 alone: → GSK agreed to buy Nuvalent for $10.6 billion → Vertex is acquiring Crinetics Pharmaceuticals for $10 billion → Novartis bought Avidity Biosciences for $12 billion at a 46% premium This is the new pharma playbook. Internal R&D takes decades, but buying late-stage biotech assets is faster, more predictable, and increasingly the only way to protect revenue against patent cliffs. A ~49% premium sounds expensive until you compare it to the cost of having no pipeline when your patent runs out. SLS will keep on running towards its ultimate base upon upcoming Catalysts and Finally bidding war $240.00+
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 22 at 7:36 PM
$SLS Super BAT(LOL) / Aza +VEN Recently FAILED 3 Large Phase 3 Trials Conducted by $ABBV - Including the VIALE-M - AML REMISSION MAINTENANCE TRIAL ... Yes Aza+VEN Killed 23% of the VIALE-A Trial Patients Taking Aza+VEN ... You go get that SUPER BAT...
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 22 at 6:46 PM
$SLS $LLY $ABBV A good time to be Loading in... Phase 3 Results will give Gps the FDA Green Light to Generate Tens of Billions of dollars in Real revenue worth $50B to Big Pharma - and the 80th Event PR is Imminent. Cr2/3 TAM Discussion NOTE: once topline Results are IN, there will be No question Regarding GPS FDA APPROVAL - and this is the Valuation Model at that Moment.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 22 at 6:42 PM
$SLS $ABBV @MJPTrades are you another Lying Short Con ?? -- a ton more in depth? there is zero factual basis for that short horse shit. so many lies / fabrications as a Single Example: the OCV501 P2 CR1 Trial confirms Gps efficacy as 1 single counter point. and compare SLS Now to back in Jan 2024 when the idmc unblinded actual p3 mos and ir data -- SHARE PRICE -- MARKET CAP -- FUNDS INVESTED -- CASH ON HAND -- all up more than 1,000% ... smarter money than the idiot retail lemmings on this board ... KNOW.
0 · Reply
Andy_1971
Andy_1971 Jul. 22 at 6:27 PM
0 · Reply
Latest News on ABBV
AbbVie price target raised to $282 from $273 at Canaccord

2026-07-22T10:40:12.000Z - 1 day ago

AbbVie price target raised to $282 from $273 at Canaccord


AbbVie price target raised to $260 from $230 at Citi

2026-07-15T10:21:06.000Z - 8 days ago

AbbVie price target raised to $260 from $230 at Citi


AbbVie price target raised to $260 from $230 at UBS

2026-07-13T16:30:09.000Z - 10 days ago

AbbVie price target raised to $260 from $230 at UBS


AbbVie price target raised to $300 from $258 at BMO Capital

2026-07-13T12:27:09.000Z - 10 days ago

AbbVie price target raised to $300 from $258 at BMO Capital


AbbVie price target raised to $280 from $260 at RBC Capital

2026-07-10T13:10:21.000Z - 13 days ago

AbbVie price target raised to $280 from $260 at RBC Capital


AbbVie price target raised to $276 from $234 at BofA

2026-07-10T10:31:16.000Z - 13 days ago

AbbVie price target raised to $276 from $234 at BofA


AbbVie price target raised to $295 from $260 at Wells Fargo

2026-07-10T10:20:22.000Z - 13 days ago

AbbVie price target raised to $295 from $260 at Wells Fargo


AbbVie price target raised to $280 from $260 at JPMorgan

2026-07-09T12:06:14.000Z - 14 days ago

AbbVie price target raised to $280 from $260 at JPMorgan


AbbVie price target raised to $261 from $249 at Guggenheim

2026-07-09T11:30:42.000Z - 14 days ago

AbbVie price target raised to $261 from $249 at Guggenheim


AbbVie says Q2 EPS to include unfavorable impact of 17c

2026-07-06T20:20:39.000Z - 16 days ago

AbbVie says Q2 EPS to include unfavorable impact of 17c


AbbVie price target raised to $300 from $275 at HSBC

2026-07-06T14:20:07.000Z - 17 days ago

AbbVie price target raised to $300 from $275 at HSBC


AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 27 days ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call


AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 4 weeks ago

AbbVie's $11 Billion Immunology Bet

APGE


AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 4 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 4 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 4 weeks ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 4 weeks ago

AbbVie Declares Quarterly Dividend


US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 2 months ago

US FDA approves AbbVie's rare blood cancer drug


AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 2 months ago

AbbVie Transcript: AGM 2026


AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 3 months ago

AbbVie Earnings Call Transcript: Q1 2026


AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 3 months ago

AbbVie Earnings release: Q1 2026


AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 3 months ago

AbbVie Quarterly report: Q1 2026


AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 3 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth


AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 3 months ago

AbbVie Reports First-Quarter 2026 Financial Results


VeltrixCapitalOfficial
VeltrixCapitalOfficial Jul. 23 at 3:29 PM
$ABBV $ABBV @.25 | +120% đŸ”„đŸ”„đŸ”„ SOLD MOST , LEFT RUNNERS
0 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial Jul. 23 at 2:47 PM
$ABBV @.18 | +60% đŸ”„đŸ”„đŸ”„ SOLD MOST , LEFT RUNNERS TURN MY NOTIFICAITONS ON
0 · Reply
liamsniperalert
liamsniperalert Jul. 23 at 2:16 PM
7/24 $ABBV 265c @​ .13
0 · Reply
stagetwotrading
stagetwotrading Jul. 23 at 1:22 PM
$ABBV - Grade A+ Stop loss @ 236.72
0 · Reply
10xorbust
10xorbust Jul. 23 at 10:53 AM
$SLS the entire purpose of bear posts like this is to scare new investors into selling. Those of us have been here for a long time tend to ignore these posts and are completely un persuaded. The purpose of this response is for the benefit of the new investors who are the targets of this nonsense. First of all with a username like Seedy do we really need to say more? Seedy is pretty much exactly what the content is of this user’s substance. Seedy’s “high probability of failure” thesis is a house of cards built on a foundations of quicksand - a sea of assumptions being presented as facts. They are no such thing. First, Seedy is assuming the BAT arm of Regal is dramatically outperforming because the trial has taken longer than expected. Nonsense. Regal is still blinded. Nobody outside the IMDC knows whether the longer survival is coming from GPS, BAT, or both. Saying “the control WILL outperform” isn’t analysi - it’s speculation. ïżŒ Moreover the historical studies of how BAT performs ïżŒ and maintaining remission or not on CD side, they cut the other way and demonstrate that these drugs do not maintain remission for long periods of time, especially at the CR2 stage. Indeed, when the leading BAT drugs in Regal, Ven/Aza were put through a phase 3 clinical trial for AML remission maintenance, the manufacturer HALTED the trial midstream - citing low enrollment. Surely, $ABBV a major pharmaceutical company with every financial incentive for this trial to finish if it were to be successful and put these drugs on the market for CR two maintenance could’ve and would’ve solved this problem if it thought the trial would be successful. Second, Seedy completely ignores the evidence that supports GPS while highlighting only the negatives. The Phase 2 AML CR2 study for GPS showed survival that was several times longer than historical controls and is the entire reason Regal exists. Does that guarantee success? Of course not. But pretending it never happened isn’t an honest review of the data. It is nothing but bear FUD. Seedy also treats every prior GPS study as a “failure,” which simply isn’t true. Several studies demonstrated strong WT1 immune responses and encouraging survival signals but were small, early-stage trials that weren’t designed to prove efficacy. There’s a huge difference between “not statistically definitive” and “the mechanism doesn’t work.” Seedy also ignores the growing body of evidence that WT1 vaccines can generate meaningful anti-leukemia immune responses. The recent pediatric WT1 vaccine study produced excellent long-term survival and showed that patients who mounted an immune response lived dramatically longer. Different study? Yes. Different vaccine? Yes. But it directly contradicts the claim that WT1 vaccines are biologically incapable of working. Seedy’s statistical argument is misleading too. He’s acting as if Regal was designed with “no cushion.” That’s not how clinical trials work. The 0.636 hazard ratio in Regal which defines success is simply the statistical hurdle needed to declare success—not a prediction of where GPS will actually land. Finally, if the bear case is so obvious, why has Regal’s independent Data Monitoring Committee repeatedly allowed the trial to continue? They have seen the unblinded data. They stopped neither for futility nor for safety concerns. That doesn’t mean Regal will succeed—but it certainly doesn’t support the claim that failure is virtually inevitable. In short, Seedy tortures the evidence and does gyrations to back into his conclusion that Regal will fail. His calling failure a “high probability” while ignoring the strongest supporting data, dismissing positive studies, and presenting speculation as fact isn’t objective analysis—it’s cherry-picking. There are no guarantees in any phase 3 clinical trial. Regal included. But at least to me, Seedy has presented nothing making me believe that Regal is going to fail. To me the evidence points strongly the other way. To me there is no super BAT and the incredibly long survival of approximately 40% of the Regal patients a minimum of 28 months to move four years cannot be explained by BAT. Finally, are Pharma Bro and “Seedy” the same person? I don’t know that, of course. But it certainly wouldn’t shock me. Once a convicted securities fraudster with a LIFETIME BAN from the pharmaceutical industry always a securities fraudster. Of course, this is not financial advice and do your own due diligence.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jul. 23 at 2:01 AM
$SLS $ABBV $GSK $VRTX $MRK AbbVie paid a 49% premium for a drug with zero approvals. Here's why that's completely rational. Recently, AbbVie announced it would acquire Apogee Therapeutics for $10.9 billion, its largest buyout in over five years, according to Reuters. AbbVie is not alone. In 2026 alone: → GSK agreed to buy Nuvalent for $10.6 billion → Vertex is acquiring Crinetics Pharmaceuticals for $10 billion → Novartis bought Avidity Biosciences for $12 billion at a 46% premium This is the new pharma playbook. Internal R&D takes decades, but buying late-stage biotech assets is faster, more predictable, and increasingly the only way to protect revenue against patent cliffs. A ~49% premium sounds expensive until you compare it to the cost of having no pipeline when your patent runs out. SLS will keep on running towards its ultimate base upon upcoming Catalysts and Finally bidding war $240.00+
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 22 at 7:36 PM
$SLS Super BAT(LOL) / Aza +VEN Recently FAILED 3 Large Phase 3 Trials Conducted by $ABBV - Including the VIALE-M - AML REMISSION MAINTENANCE TRIAL ... Yes Aza+VEN Killed 23% of the VIALE-A Trial Patients Taking Aza+VEN ... You go get that SUPER BAT...
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 22 at 6:46 PM
$SLS $LLY $ABBV A good time to be Loading in... Phase 3 Results will give Gps the FDA Green Light to Generate Tens of Billions of dollars in Real revenue worth $50B to Big Pharma - and the 80th Event PR is Imminent. Cr2/3 TAM Discussion NOTE: once topline Results are IN, there will be No question Regarding GPS FDA APPROVAL - and this is the Valuation Model at that Moment.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 22 at 6:42 PM
$SLS $ABBV @MJPTrades are you another Lying Short Con ?? -- a ton more in depth? there is zero factual basis for that short horse shit. so many lies / fabrications as a Single Example: the OCV501 P2 CR1 Trial confirms Gps efficacy as 1 single counter point. and compare SLS Now to back in Jan 2024 when the idmc unblinded actual p3 mos and ir data -- SHARE PRICE -- MARKET CAP -- FUNDS INVESTED -- CASH ON HAND -- all up more than 1,000% ... smarter money than the idiot retail lemmings on this board ... KNOW.
0 · Reply
Andy_1971
Andy_1971 Jul. 22 at 6:27 PM
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 22 at 6:20 PM
$SLS $LLY $ABBV Day 72 This $2.36B baby bio is about to release Phase 3 Registrational results, worth 27x the current short Rigged market cap. Phase 3 Registrational Results: - 6+ years in the making are now Imminent - P3 Results that will give Gps the FDA Green light to treat 40,000 AML remission patients each year + 100,000 Currently in Remission - and generate Tens of Billions in real revenue. Tens of Billions of dollars in Real revenue worth $50B to Big Pharma - and the 80th Event PR is Imminent. Cr2/3 TAM Discussion NOTE: once topline Results are IN, there will be No question Regarding GPS FDA APPROVAL - and this is the Valuation Model at that Moment.
0 · Reply
IN0V8
IN0V8 Jul. 22 at 6:12 PM
$ABBV Buy Canaccord Genuity raises target price to $282 from $273
0 · Reply
10xorbust
10xorbust Jul. 22 at 5:41 PM
$SLS or the entire purpose of bears post like this is to scare new investors into selling. Those of us have been here for a long time tend to ignore these posts and are completely un persuaded. The purpose of this response is for the benefit of the new investors who are the targets of this nonsense. First of all with a username like Seedy do we really need to say more? Seedy is pretty much exactly what the content is of this user’s substance. Seedy’s “high probability of failure” thesis is a house of cards built on a foundations of quicksand - a sea of assumptions being presented as facts. They are no such thing. First, Seedy is assuming the BAT arm of Regal is dramatically outperforming because the trial has taken longer than expected. Nonsense. Regal is still blinded. Nobody outside the IMDC knows whether the longer survival is coming from GPS, BAT, or both. Saying “the control WILL outperform” isn’t analysi - it’s speculation. ïżŒ Moreover the historical studies of how BAT performs ïżŒ and maintaining remission or not on CD side, they cut the other way and demonstrate that these drugs do not maintain remission for long periods of time, especially at the CR2 stage. Indeed, when the leading BAT drugs in Regal, Ven/Aza were put through a phase 3 clinical trial for AML remission maintenance, the manufacturer HALTED the trial midstream - citing low enrollment. Surely, $ABBV a major pharmaceutical company with every financial incentive for this trial to finish if it were to be successful and put these drugs on the market for CR two maintenance could’ve and would’ve solved this problem if it thought the trial would be successful. Second, Seedy completely ignores the evidence that supports GPS while highlighting only the negatives. The Phase 2 AML CR2 study for GPS showed survival that was several times longer than historical controls and is the entire reason Regal exists. Does that guarantee success? Of course not. But pretending it never happened isn’t an honest review of the data. It is nothing but bear FUD. Seedy also treats every prior GPS study as a “failure,” which simply isn’t true. Several studies demonstrated strong WT1 immune responses and encouraging survival signals but were small, early-stage trials that weren’t designed to prove efficacy. There’s a huge difference between “not statistically definitive” and “the mechanism doesn’t work.” Seedy also ignores the growing body of evidence that WT1 vaccines can generate meaningful anti-leukemia immune responses. The recent pediatric WT1 vaccine study produced excellent long-term survival and showed that patients who mounted an immune response lived dramatically longer. Different study? Yes. Different vaccine? Yes. But it directly contradicts the claim that WT1 vaccines are biologically incapable of working. Seedy’s statistical argument is misleading too. He’s acting as if Regal was designed with “no cushion.” That’s not how clinical trials work. The 0.636 hazard ratio in Regal which defines success is simply the statistical hurdle needed to declare success—not a prediction of where GPS will actually land. Finally, if the bear case is so obvious, why has Regal’s independent Data Monitoring Committee repeatedly allowed the trial to continue? They have seen the unblinded data. They stopped neither for futility nor for safety concerns. That doesn’t mean Regal will succeed—but it certainly doesn’t support the claim that failure is virtually inevitable. In short, Seedy tortures the evidence and does gyrations to back into his conclusion that Regal will fail. His calling failure a “high probability” while ignoring the strongest supporting data, dismissing positive studies, and presenting speculation as fact isn’t objective analysis—it’s cherry-picking. There are no guarantees in any phase 3 clinical trial. Regal included. But at least to me, Seedy has presented nothing making me believe that Regal is going to fail. To me the evidence points strongly the other way. To me there is no super BAT and the incredibly long survival of approximately 40% of the Regal patients a minimum of 28 months to move four years cannot be explained by BAT. Of course, this is not financial advice and do your own due diligence.
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 21 at 1:54 AM
$SLS $LLY $ABBV Tomorrow will be Day 71 Since the 78th Event - 31 Day Event Rate From 60th to 72nd and 22 Days from 72nd to 78th. No REAL Holders Are Letting ANY Shares Go with the Imminent 80th Event PR and TopLINE data. *** SSR In Effect: Tomorrow may be +20% with no news {like last week}, and +200% with the 80th Event PR. all the Noise - will be silenced with the P3 Top Line Results, giving Gps, a Revolutionary AML Remission Maintenance Immunotherapy, the Fda Green Light to treat upwards of 50,000 AML Remission Patients Each Year + another 100,000 patients Currently in Remission, who live in Fear of AML Returning. NO MORE - NO MORE -- Phase 3 Results are Coming - the Future is Inevitable.
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 20 at 9:00 PM
$OTLK $ABBV If there was one day an approved alternative to repeat eye injections, that was maybe a one and done that was potentially estimated at 200k+ total for both eyes, but no treatment ever needed again, 1. What percent of people do you think might go for that? 2. What % do you think insurance might potentially cover? 3. What decade do you think gene therapy overall for all pharma might become more common?
1 · Reply
GoforProMIS
GoforProMIS Jul. 20 at 8:41 PM
$PMN exactly and more precise: Big buys shows accumulation Medium and Small selling anyway the path is clear with Alzheimer Disease, Parkinson, Schizophrenia, ALS and several other diseases with PMN310 platform medicine the biding war for big pharmaceutical companies like $BMY $JNJ $ABBV is only in beginning the main target is AD competition Eli Lilly, Biogen, Eisai and Roche-Novartis. So everyone should know what’s happening 🔜 📈
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 20 at 7:44 PM
$SLS 31.6 Days Per Event from the 60th Event on Dec 8th 2024 to the 72nd Dec 26th 2025. 22 Days Per Event from the 72nd to the 78th - on May 11. it has now Been 70 Days ... One thing I've been intrigued by, 3 Partners in the Launch of the SLS Rocket -- feels like $ABBV buys 009 $MRK and $BMY Take GPS. BE HOLDING.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 20 at 7:36 PM
$SLS BAT Since 2018 -- https://www.fda.gov/drugs/fda-approves-venetoclax-combination-aml-adults - It is Now DAY 70... No Real Holders are letting any shares go, now this close to the 80th Event PR Incoming THIS Week and the following Phase 3 Results, that are worth 27x the current Share price. ​$20 - $25 THIS WEEK on the 80th Event PR and climbing 10x+ $135 per share on the P3 Results. Mark this Post. Gps is about to get a Fda green light to Generate Tens of Billions in Real Revenue - worth every nickel of $40B to $PFE $LLY $ABBV DAY 70 ...
0 · Reply
GoforProMIS
GoforProMIS Jul. 20 at 5:02 PM
$PMN looks nice today with +10% . It seems big Pharma knows something about the results of PMN310 Alzheimer disease and the platform for several other diseases like Parkinson, ALS, Schizophrenia etc. https://www.promisneurosciences.com/news-media/press-releases/detail/269/promis-neurosciences-reports-first-human-evidence-of $ABBV $AMRX $RHHBY $TEVA
0 · Reply
GoforProMIS
GoforProMIS Jul. 20 at 4:51 PM
$PMN shows up today with +10% It seems big Pharma knows something about the results of PMN310 Alzheimer disease and the platform for several other diseases like Parkinson, ALS, Schizophrenia etc. https://www.promisneurosciences.com/news-media/press-releases/detail/269/promis-neurosciences-reports-first-human-evidence-of $ABBV $AMRX $NVS$TEVA
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 20 at 2:47 PM
$RGNX New here. 1. For the #DD people-is there a source you know of with an estimated range for treatment for wet AMD, retina, DME etc. estimated cost per treatment per eye 2. When is the trial end date for eyes? 3. Does anyone know any stocks that were considered gene therapy and how smooth insurance might go for that? 4. Is $ABBV doing some kind of 50/50 thing on multiple/all or only one in development? 5. What are the optimistic and pessimistic targets for percent of the market for wet AMD?
1 · Reply
opt_guru101
opt_guru101 Jul. 20 at 1:27 PM
$ABBV 252 support
0 · Reply